ATH has not said anything about why this was done and what is written in this agreement or royalties etc. However, ATH has also done AD-related research with ATH434 (?) but has not published anything about them. Brain injury and eye degeneration have also been studied and in these iron accumulation seems to be the main thing. Finkelstein has even published a few eye-related papers. To me, it looks like ATH is interested in iron overload and not so much in zinc chelation in spite of it has also new zinc-related molecules.
Now the main effort is to complete the ph 2 study. It is to get rid of accumulated iron in the brain, first in MSA and later in PD. This new Chinese paper I just posted about the hippocampus and neurogenesis (Jie Li et al ) makes it clear that accumulated iron is also strongly related to the AD process.
Masters has been interested in zinc and looks like ATH is targeting iron. PBT2 is not only a zinc chelator but also an iron chelator as ATH434 chelates also zinc. So the role of iron and zinc is important to both zinc and iron chelation drugs. But at present it looks like ATH wanted to concentrate on iron and give zinc chelation to Masters.
Just my speculation, nothing else.
ATH Price at posting:
0.7¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)